Pfizer Inc. (PFE) Financials Nov 14, 2014, 7:58

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Pfizer Inc. (PFE) Financials Nov 14, 2014, 7:58 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Pfizer Inc.


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 50.01B 67.06B 65.26B 58.99B 51.58B
Cost of Goods Sold (COGS) incl. D&A 11.59B 20.71B 18.82B 16.21B 13.95B
COGS excluding D&A 6.83B 12.23B 9.91B 8.6B 7.54B
Depreciation & Amortization Expense 4.76B 8.49B 8.91B 7.61B 6.41B
Depreciation 1.76B 3.08B 3.11B 2.21B 1.61B
Amortization of Intangibles 3B 5.4B 5.8B 5.4B 4.8B
Gross Income 38.42B 46.34B 46.44B 42.78B 37.63B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 22.41B 28.61B 27.13B 23.81B 20.74B
Research & Development 7.75B 9.36B 8.4B 7.34B 6.55B
Other SG&A 14.66B 19.25B 18.73B 16.47B 14.19B
Other Operating Expense 0 0 0 0 0
Unusual Expense 5.96B 8.03B 6.36B 6.19B 1.26B
EBIT after Unusual Expense (5.96B) (8.03B) (6.36B) (6.19B) (1.26B)
Non Operating Income/Expense 787M 971M 577M 447M 642M
Non-Operating Interest Income 746M 402M 456M 383M 403M
Equity in Affiliates (Pretax) 482M 0 - - 459M
Interest Expense 1.23B 1.8B 1.68B 1.52B 1.41B
Gross Interest Expense 1.27B 1.83B 1.73B 1.57B 1.45B
Interest Capitalized 34M 36M 50M 41M 32M
Pretax Income 10.83B 9.28B 12.3B 12.08B 15.72B
Income Tax 2.2B 1.07B 3.91B 2.56B 4.31B
Income Tax - Current Domestic 10.24B (3.08B) 1.56B (796M) 36M
Income Tax - Current Foreign 1.54B 2.21B 2.05B 2.62B 2.54B
Income Tax - Deferred Domestic (10.1B) 2B 124M 523M 2.09B
Income Tax - Deferred Foreign 513M (67M) 183M 216M (365M)
Income Tax Credits 0 0 - - 0
Equity in Affiliates 0 0 - - 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 8.63B 8.21B 8.4B 9.52B 11.41B
Minority Interest Expense 9M 31M 40M 28M 30M
Net Income 8.62B 8.18B 8.36B 9.49B 11.38B
Extraordinaries & Discontinued Operations 14M 77M 1.65B 5.08B 10.62B
Extra Items & Gain/Loss Sale Of Assets 0 (11M) 1.3B 4.78B 10.35B
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 14M 88M 350M 297M 269M
Net Income After Extraordinaries 8.64B 8.26B 10.01B 14.57B 22B
Preferred Dividends 2M 2M 2M 2M 2M
Net Income Available to Common 8.62B 8.18B 8.35B 9.49B 11.38B
EPS (Basic) 1.23 1.03 1.11 1.31 1.71
Basic Shares Outstanding 7.01B 8.04B 7.82B 7.44B 6.81B
EPS (Diluted) 1.23 1.02 1.11 1.30 1.69
Diluted Shares Outstanding 7.05B 8.07B 7.87B 7.51B 6.9B
EBITDA 20.77B 26.22B 28.22B 26.58B 23.3B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 8

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 10

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 12

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 11

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 9

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 14

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 15

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Mercury Capital Secures $4.35M Loan for Retail Hub

Updated Category News Views 21

Mercury Capital Partners Banks on Retail Development They say the beauty's in the numbers, but the magic happens when you make those numbers work for you. Mercury Capital Partners (MCP) is wrangling dollars like no one's business, pushing a $4.35 million construction loan into the Fort Myers scene like it's a walk in the park. We're looking at Estero Oaks, a...

Continue Reading
Amazon Analysts Update Forecasts for Upcoming Earnings Report

Updated Category News Views 130

Amazon's Upcoming Earnings Call Amazon.com, Inc. (NASDAQ: AMZN) is set to unveil its earnings results for the second quarter. This announcement will provide valuable insights into the company's financial health and operational performance. Market expectations are leaning toward a positive outlook, as analysts predict robust earnings and revenue growth. Predicted Earnings...

Continue Reading
Understanding the Recent Surge in ServiceNow Options Activity

Updated Category News Views 82

Understanding the Recent Surge in ServiceNow Options Activity Recently, a notable shift occurred in the options market surrounding ServiceNow (NYSE: NOW), drawing attention from both institutional and retail investors. With deep pockets behind these moves, it's crucial to analyze what it could mean for the future of the stock. It’s always intriguing when a significant...

Continue Reading
Join the Exciting Bybit Boost Battle for Weekly USDT Prizes!

Updated Category News Views 176

Join the Exciting Bybit Boost Battle for Weekly USDT Prizes! Bybit, recognized as the second-largest cryptocurrency exchange globally by trading volume, has initiated a vibrant competition called the Boost Battle. This thrilling event allows traders to participate weekly, showcasing their skills and strategies. The grand prize rolls out weekly, presenting winners with the...

Continue Reading
Desert Control's Q2 Progress: Innovations and Financial Insights

Updated Category News Views 190

Desert Control's Q2 2025 Report Summary Desert Control AS (DSRT) has made commendable strides in the second quarter of 2025, revealing significant operational achievements and promising financial results. This report encapsulates the journey and progress of the company, focusing on their innovative solutions that enhance soil health and water conservation. Operational...

Continue Reading